Medical researchers have discovered how effective a new drug that treats colorectal cancer is, as virtually every member of a clinical trial got cured.
The drug is Dostartlimab, a monoclonal antibody drug, which exceeded expectations in a recent trial that was run by Memorial Slon Kettering Cancer Center in New York.
The trial was sponsored by GlaxoSmithKline (GSK), the pharmaceutical giant.
Doctors were unable to find signs of cancer in the body of each of the 18 participants in the trial who had their disease go into complete remission one year after the trial’s completion.
While the trial was small, it is considered game-changing and sets up the drug as a potential cure for one of the most dangerous common cancers known
The treatment is for those with tumours of a specific genetic makeup known as mismatch repair-deficient (MMRd) or microsatellite instability (MSI).
READ ALSO: Throat cancer signs that should not be ignored to avoid complications
Patients in the study received monoclonal antibody treatments every three weeks for six months
The 18 patients who took part in the trial had gone through chemotherapy, risky surgeries, and other treatments for colorectal cancer before the trial.
The drug works by ‘unmasking’ cancer cells that are hiding, allowing the immune system to identify and destroy them.
After following up with patients 12 months later, researchers noticed that the cancer had seemingly vanished from their bodies, with the medical staff unable to find signs of tumours with any of the available screening methods. Thereafter, no further treatments were required.
At present, a total of 12 patients have completed the treatment and undergone at least six months of follow-up.
In the meantime, the positive results have only been seen in those 12 patients so far (the trial is ongoing)
Cancer is one of the leading causes of death worldwide as new cases, and deaths from the disease keep rising.
READ ALSO: Signs of kidney cancer that can be felt on some other parts of the body
According to the World Health Organization’s (WHO) International Agency for the Research on Cancer, Nigeria is currently estimated to have 233,911 cancer cases, with 124,815 new cases and 78,899 cancer deaths yearly from its population of over 200 million people.
Studies show that if the current trend is maintained, the cancer burden in Africa is projected to double from 1,055,172 new cancer cases in 2018 to 2,123,245 by 2040.
Colorectal cancer (CRC) incidence and mortality is gradually rising in sub-Saharan Africa.
CRC is now the 4th most common cancer in the World Health Organization-Africa region. This rising burden is reflected in Nigeria, where more than half of the patients die within one year of diagnosis.
It is estimated that 49,190 colorectal deaths occurred in Nigeria in 2016. Colorectal cancer is the third most common cancer in Nigerian men (after prostate and liver cancer) and the fourth most common cancer in Nigerian women (after breast, cervical, and liver cancer).